{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T10:22:20Z","timestamp":1791973340639,"version":"4.3.4"},"reference-count":85,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2014,6,10]],"date-time":"2014-06-10T00:00:00Z","timestamp":1402358400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1007\/s40618-014-0097-2","type":"journal-article","created":{"date-parts":[[2014,6,10]],"date-time":"2014-06-10T21:21:10Z","timestamp":1402435270000},"page":"691-700","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":233,"title":["Extrathyroidal manifestations of Graves\u2019 disease: a 2014 update"],"prefix":"10.1007","volume":"37","author":[{"given":"Luigi","family":"Bartalena","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vahab","family":"Fatourechi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,6,10]]},"reference":[{"key":"97_CR1","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1038\/nrendo.2013.193","volume":"9","author":"L Bartalena","year":"2013","unstructured":"Bartalena L (2013) Diagnosis and management of Graves disease: a global overview. Nat Rev Endocrinol 9:724\u2013734","journal-title":"Nat Rev Endocrinol"},{"key":"97_CR2","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1111\/cen.12060","volume":"78","author":"H Filipsson Nystrom","year":"2013","unstructured":"Filipsson Nystrom H, Jansson S, Berg G (2013) Incidence rate and clinical features of hyperthyroidism in a long-term iodine sufficient area of Sweden (Gothenburg) 2003\u20132005. Clin Endocrinol (Oxf) 78:768\u2013776","journal-title":"Clin Endocrinol (Oxf)"},{"key":"97_CR3","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMcp0806317","volume":"360","author":"L Bartalena","year":"2009","unstructured":"Bartalena L, Tanda ML (2009) Clinical practice, Graves\u2019 ophthalmopathy. N Engl J Med 360:994\u20131001","journal-title":"N Engl J Med"},{"key":"97_CR4","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.beem.2011.10.001","volume":"26","author":"V Fatourechi","year":"2012","unstructured":"Fatourechi V (2012) Thyroid dermopathy and acropachy. Best Pract Res Clin Endocrinol Metab 26:553\u2013565","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"97_CR5","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1210\/jc.2012-3873","volume":"98","author":"ML Tanda","year":"2013","unstructured":"Tanda ML, Piantanida E, Liparulo L, Veronesi G, Lai A, Sassi L, Pariani N, Gallo D, Azzolini C, Ferrario M, Bartalena L (2013) Prevalence and natural history of Graves\u2019 orbitopathy in a large series of patients with newly diagnosed Graves\u2019 hyperthyroidism seen at a single center. J Clin Endocrinol Metab 98:1443\u20131449","journal-title":"J Clin Endocrinol Metab"},{"key":"97_CR6","first-page":"444","volume":"36","author":"E Piantanida","year":"2013","unstructured":"Piantanida E, Tanda ML, Lai A, Sassi L, Bartalena L (2013) Prevalence and natural history of Graves\u2019 orbitopathy in the XXI century. J Endocrinol Invest 36:444\u2013449","journal-title":"J Endocrinol Invest"},{"key":"97_CR7","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S0002-9394(14)70276-4","volume":"121","author":"GB Bartley","year":"1996","unstructured":"Bartley GB, Fatourechi V, Kadarmas EF, Jacobson SJ, Ilstrup DM, Gorman CA (1996) Clinical features of Graves\u2019 ophthalmopathy in an incidence cohort. Am J Ophthalmol 121:284\u2013289","journal-title":"Am J Ophthalmol"},{"key":"97_CR8","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/BF03348875","volume":"16","author":"V Fatourechi","year":"1993","unstructured":"Fatourechi V, Garrity JA, Bartley GB, Bergstralh EJ, Gorman CA (1993) Orbital decompression in Graves\u2019 opthalmopathy associated with pretibial myxedema. J Endocrinol Invest 16:433\u2013437","journal-title":"J Endocrinol Invest"},{"key":"97_CR9","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/MAJ.0b013e318288a6fa","volume":"346","author":"S Lohiya","year":"2013","unstructured":"Lohiya S, Lohiya V, Stahl EJ (2013) Pretibial myxedema without ophthalmopathy: an initial presentation of Graves\u2019 disease. Am J Med Sci 346:73\u201375","journal-title":"Am J Med Sci"},{"key":"97_CR10","first-page":"125","volume":"23","author":"F Capsoni","year":"2005","unstructured":"Capsoni F, Minonzio F, Sarzi-Puttini P, Atzeni F, Ambrosi B (2005) Thyroid acropachy: an unusual rheumatic manifestation of Graves\u2019 disease. Clin Exp Rheumatol 23:125\u2013126","journal-title":"Clin Exp Rheumatol"},{"key":"97_CR11","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S0002-9394(14)72666-2","volume":"120","author":"GB Bartley","year":"1995","unstructured":"Bartley GB, Fatourechi V, Kadarmas EF, Jacobsen SJ, Ilstrup DL, Garrity JA, Gorman CA (1995) The incidence of Graves\u2019 ophthalmopathy in Olmsted County Minnesota. Am J Opthalmol 120:511\u2013517","journal-title":"Am J Opthalmol"},{"key":"97_CR12","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1056\/NEJMra0905750","volume":"362","author":"RS Bahn","year":"2010","unstructured":"Bahn RS (2010) Mechanisms of disease: Graves\u2019 ophthalmopathy. N Engl J Med 362:726\u2013738","journal-title":"N Engl J Med"},{"key":"97_CR13","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1007\/BF03346614","volume":"33","author":"TJ Smith","year":"2010","unstructured":"Smith TJ (2010) Pathogenesis of Graves\u2019 orbitopathy: a 2010 update. J Endocrinol Invest 33:414\u2013421","journal-title":"J Endocrinol Invest"},{"key":"97_CR14","first-page":"168","volume":"21","author":"L Bartalena","year":"2000","unstructured":"Bartalena L, Pinchera A, Marcocci C (2000) Management of Graves\u2019 ophthalmopathy: reality and perspectives. Endocr Rev 21:168\u2013199","journal-title":"Endocr Rev"},{"key":"97_CR15","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.beem.2011.10.003","volume":"26","author":"S Iyer","year":"2012","unstructured":"Iyer S, Bahn RS (2012) Immunopathogenesis of Graves\u2019 ophthalmopathy: the role of the TSH receptor. Best Pract Res Clin Endocrinol Metab 26:281\u2013299","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"97_CR16","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1210\/en.2013-1576","volume":"154","author":"S Moshkelgosha","year":"2013","unstructured":"Moshkelgosha S, So P-W, Deasy N, Diaz-Cano S, Banga JP (2013) Cutting edge: retrobulbar inflammation, adipogenesis, and acute orbital congestion in a preclinical female mouse model of Graves\u2019 orbitopathy induced by thyrotropin receptor plasmid in vitro electroporation. Endocrinology 154:3008\u20133015","journal-title":"Endocrinology"},{"key":"97_CR17","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.beem.2011.10.002","volume":"26","author":"TJ Smith","year":"2012","unstructured":"Smith TJ, Huetwell FGL, Hegedus L, Douglas RS (2012) Role of insulin-like growth factor-1 (IGF-1) pathway in the pathogenesis of Graves\u2019 orbitopathy. Best Pract Res Clin Endocrinol Metab 26:291\u2013302","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"97_CR18","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1210\/jc.2011-0307","volume":"96","author":"WM Wiersinga","year":"2011","unstructured":"Wiersinga WM (2011) Autoimmunity in Graves\u2019 ophthalmopathy: the result of an unfortunate marriage between TSH receptors and IGF-1 receptors? J Clin Endocrinol Metab 96:2386\u20132394","journal-title":"J Clin Endocrinol Metab"},{"key":"97_CR19","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1530\/EJE-11-0055","volume":"164","author":"S Estcourt","year":"2009","unstructured":"Estcourt S, Quinn AG, Vaidya BJ (2009) Quality of life in thyroid eye disease: impact of quality of care. Eur J Endocrinol 164:649\u2013655","journal-title":"Eur J Endocrinol"},{"key":"97_CR20","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1530\/eje.1.02230","volume":"155","author":"WM Wiersinga","year":"2006","unstructured":"Wiersinga WM, Perros P, Kahaly GJ, Mourits MP, Baldeschi L, Boboridis K, Boschi A, Dickinson AJ, Kendall-Taylor P, Krassas GE, Lane CM, Lazarus JH, Marcocci C, Marin\u00f2 M, Nardi M, Neoh C, Orgiazzi J, Pinchera A, Pitz S, Prummel MF, Sartini MS, Stahl M, von Arx G (2006) Clinical assessment of patients with Graves\u2019 orbitopathy: the European Group on Graves\u2019 Orbitopathy recommendations to generalists, specialists and clinical researchers. Eur J Endocrinol 155:387\u2013389","journal-title":"Eur J Endocrinol"},{"key":"97_CR21","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/01.iop.0000235499.34867.85","volume":"22","author":"PJ Dolman","year":"2006","unstructured":"Dolman PJ, Rootman J (2006) VISA classification for Graves\u2019 orbitopathy. Ophthal Plast Reconstr Surg 22:319\u2013324","journal-title":"Ophthal Plast Reconstr Surg"},{"key":"97_CR22","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1046\/j.1365-2265.1997.2331047.x","volume":"47","author":"MP Mourits","year":"1997","unstructured":"Mourits MP, Prummel MF, Wiersinga WM, Koornneef L (1997) Clinical activity score as a guide in the management of patients with Graves\u2019 ophthalmopathy. Clin Endocrinol (Oxf) 47:9\u201314","journal-title":"Clin Endocrinol (Oxf)"},{"key":"97_CR23","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1530\/EJE-07-0666","volume":"158","author":"L Bartalena","year":"2008","unstructured":"Bartalena L, Baldeschi L, Dickinson AJ, Eckstein A, Kendall-Taylor P, Marcocci C, Mourits M, Perros P, Boboridis K, Boschi A, Curr\u00f2 N, Daumerie C, Kahaly GJ, Krassas GE, Lane CM, Lazarus JH, Nardi M, Neoh C, Orgiazzi J, Pearce S, Pinchera A, Pitz S, Salvi M, Sivelli P, Stahl M, von Arx G, Wiersinga WM (2008) Consensus statement of the European Group on Graves\u2019 orbitopathy (EUGOGO) on management of GO. Eur J Endocrinol 158:273\u2013285","journal-title":"Eur J Endocrinol"},{"key":"97_CR24","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.beem.2011.09.004","volume":"26","author":"L Bartalena","year":"2012","unstructured":"Bartalena L (2012) Prevention of Graves\u2019 ophthalmopathy. Best Pract Res Clin Endocrinol Metab 26:371\u2013379","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"97_CR25","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1046\/j.1365-2265.1996.8220832.x","volume":"45","author":"J Pfeilschifter","year":"1996","unstructured":"Pfeilschifter J, Ziegler R (1996) Smoking and endocrine ophthalmopathy: impact of smoking severity and current versus lifetime cigarette consumption. Clin Endocrinol (Oxf) 45:477\u2013481","journal-title":"Clin Endocrinol (Oxf)"},{"key":"97_CR26","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1001\/archinte.1990.00390170124027","volume":"150","author":"MF Prummel","year":"1990","unstructured":"Prummel MF, Wiersinga WM, Mourits MP, Koornneef L, Berghout A, van der Gaag R (1990) Effect of abnormal thyroid function on the severity of Graves\u2019 ophthalmopathy. Arch Intern Med 150:1098\u20131101","journal-title":"Arch Intern Med"},{"key":"97_CR27","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1056\/NEJM199801083380201","volume":"338","author":"L Bartalena","year":"1998","unstructured":"Bartalena L, Marcocci C, Bogazzi F, Manetti L, Tanda ML, Dell\u2019Unto E, Bruno-Bossio G, Nardi M, Bartolomei MP, Lepri A, Rossi G, Martino E, Pinchera A (1998) Relation between therapy for hyperthyroidism and the course of Graves\u2019 ophthalmopathy. N Engl J Med 338:73\u201378","journal-title":"N Engl J Med"},{"key":"97_CR28","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1210\/jc.2009-2130","volume":"95","author":"A Lai","year":"2010","unstructured":"Lai A, Sassi L, Compri E, Marino F, Sivelli P, Piantanida E, Tanda ML, Bartalena L (2010) Lower dose prednisone prevents radioiodine-associated exacerbation of initially mild or absent Graves\u2019 orbitopathy: a retrospective cohort study. J Clin Endocrinol Metab 95:1333\u20131337","journal-title":"J Clin Endocrinol Metab"},{"key":"97_CR29","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1530\/EJE-07-0450","volume":"158","author":"P Laurberg","year":"2008","unstructured":"Laurberg P, Wallin G, Tallstedt L, Abraham-Nordling M, Lundell G, T\u00f8rring O (2008) TSH-receptor autoimmunity in Graves\u2019 disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective randomized study. Eur J Endocrinol 158:69\u201375","journal-title":"Eur J Endocrinol"},{"issue":"10","key":"97_CR30","first-page":"15","volume":"36","author":"C Marcocci","year":"2013","unstructured":"Marcocci C, Bartalena L (2013) Role of oxidative stress and selenium in Graves\u2019 hyperthyroidism and orbitopathy. J Endocrinol Invest 36(10):15\u201320","journal-title":"J Endocrinol Invest"},{"issue":"10","key":"97_CR31","first-page":"1","volume":"36","author":"J Kohrle","year":"2013","unstructured":"Kohrle J (2013) Pathophysiological relevance of selenium. J Endocrinol Invest 36(10):1\u20137","journal-title":"J Endocrinol Invest"},{"issue":"10","key":"97_CR32","first-page":"8","volume":"36","author":"D Nacamulli","year":"2013","unstructured":"Nacamulli D, Petricca D, Mian C (2013) Selenium and autoimmune thyroiditis. J Endocrinol Invest 36(10):8\u201314","journal-title":"J Endocrinol Invest"},{"key":"97_CR33","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1056\/NEJMoa1012985","volume":"364","author":"C Marcocci","year":"2011","unstructured":"Marcocci C, Kahaly GJ, Krassas GE, Bartalena L, Prummel M, Stahl M, Altea MA, Nardi M, Pitz S, Boboridis K, Sivelli P, von Arx G, Mourits MP, Baldeschi L, Bencivelli W, Wiersinga M, European Group on Graves\u2019 Orbitopathy (2011) Selenium and the course of mild Graves\u2019 orbitopathy. N Engl J Med 364:1920\u20131931","journal-title":"N Engl J Med"},{"key":"97_CR34","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.beem.2011.11.002","volume":"26","author":"A Eckstein","year":"2012","unstructured":"Eckstein A, Schittkowski M, Esser J (2012) Surgical treatment of Graves\u2019 ophthalmopathy. Best Pract Res Clin Endocrinol Metab 26:339\u2013358","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"97_CR35","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1210\/jc.2010-1962","volume":"96","author":"S Zang","year":"2011","unstructured":"Zang S, Ponto KA, Kahaly GJ (2011) Intravenous glucocorticoids for Graves\u2019 orbitopathy: efficacy and morbidity. J Clin Endocrinol Metab 96:320\u2013332","journal-title":"J Clin Endocrinol Metab"},{"key":"97_CR36","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1007\/BF03346732","volume":"34","author":"S Zang","year":"2011","unstructured":"Zang S, Ponto KA, Pitz S, Kahaly GJ (2011) Dose of intravenous steroids and therapy outcome in Graves\u2019 orbitopathy. J Endocrinol Invest 34:876\u2013880","journal-title":"J Endocrinol Invest"},{"key":"97_CR37","doi-asserted-by":"crossref","first-page":"4454","DOI":"10.1210\/jc.2012-2389","volume":"97","author":"L Bartalena","year":"2012","unstructured":"Bartalena L, Krassas GE, Wiersinga W, Marcocci C, Salvi M, Daumerie C, Bournaud C, Stahl M, Sassi L, Veronesi G, Azzolini C, Boboridis KG, Mourits MP, Soeters MR, Baldescxhi L, Nardi M, Curr\u00f2 N, Boschi A, Bernard M, von Arx G, European Group on Graves\u2019 Orbitopathy (2012) Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves\u2019 orbitopathy. J Clin Endocrinol Metab 97:4454\u20134463","journal-title":"J Clin Endocrinol Metab"},{"key":"97_CR38","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1089\/thy.2006.0267","volume":"17","author":"R Moli Le","year":"2007","unstructured":"Le Moli R, Baldeschi L, Saeed P, Regensburg N, Mourits MP, Wiersinga WM (2007) Determinants of liver damage associated with intravenous methylprednisolone pulse therapy in Graves\u2019 ophthalmopathy. Thyroid 17:357\u2013362","journal-title":"Thyroid"},{"key":"97_CR39","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1365-2265.2010.03783.x","volume":"73","author":"L Bartalena","year":"2010","unstructured":"Bartalena L (2010) What to do for moderate-to-severe and active Graves\u2019 orbitopathy if glucocorticoids fail? Clin Endocrinol (Oxf) 73:149\u2013152","journal-title":"Clin Endocrinol (Oxf)"},{"key":"97_CR40","doi-asserted-by":"crossref","first-page":"3857","DOI":"10.1210\/jc.2012-2758","volume":"97","author":"ML Tanda","year":"2012","unstructured":"Tanda ML, Bartalena L (2012) Efficacy and safety of orbital radiotherapy for Graves\u2019 orbitopathy. J Clin Endocrinol Metab 97:3857\u20133865","journal-title":"J Clin Endocrinol Metab"},{"key":"97_CR41","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1056\/NEJM198911163212002","volume":"321","author":"MF Prummel","year":"1989","unstructured":"Prummel MF, Mourits MP, Berghout L (1989) Prednisone and cyclosporine in the treatment of severe Graves\u2019 ophthalmopathy. N Engl J Med 321:1353\u20131359","journal-title":"N Engl J Med"},{"key":"97_CR42","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1530\/EJE-09-0383","volume":"161","author":"S Estcourt","year":"2009","unstructured":"Estcourt S, Hickey J, Perros P, Dayan C, Vaidya B (2009) The patient experience of services for thyroid eye disease in the UK: results of a nationwide survey. Eur J Endocrinol 161:483\u2013487","journal-title":"Eur J Endocrinol"},{"key":"97_CR43","doi-asserted-by":"crossref","first-page":"9","DOI":"10.5070\/D347X2X5FG","volume":"19","author":"S Verma","year":"2013","unstructured":"Verma S, Rongioletti F, Braun-Falco M, Ruzicka T (2013) Preradial myxedema in a euthyroid male: a distinct rarity. Dermatol Online J 19:9","journal-title":"Dermatol Online J"},{"key":"97_CR44","first-page":"438","volume":"87","author":"KM Schwartz","year":"2002","unstructured":"Schwartz KM, Fatourechi V, Ahmed DF, Pond GR (2002) Dermopathy of Graves\u2019 disease (pretibial myxedema): long term outcome. J Clin Endocrinol Metab 87:438\u2013446","journal-title":"J Clin Endocrinol Metab"},{"key":"97_CR45","doi-asserted-by":"crossref","first-page":"209","DOI":"10.4149\/endo_2011_04_209","volume":"45","author":"E Karoutsou","year":"2011","unstructured":"Karoutsou E, Polymeris A (2011) Pathogenesis of Graves\u2019 disease focusing on Graves\u2019 ophthalmopathy. Endocr Regul 45:209\u2013220","journal-title":"Endocr Regul"},{"key":"97_CR46","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1530\/EJE-10-1095","volume":"164","author":"SR Shih","year":"2011","unstructured":"Shih SR, Lin MS, Li HY, Yang HY, Hsiao YL, Chang MT, Chen CM, Chang TC (2011) Observing pretibial myxedema in patients with Graves\u2019 disease using digital infrared thermal imaging and high-resolution ultrasonography: for better records, early detection, and further investigation. Eur J Endocrinol 164:605\u2013611","journal-title":"Eur J Endocrinol"},{"key":"97_CR47","doi-asserted-by":"crossref","first-page":"295","DOI":"10.2165\/00128071-200506050-00003","volume":"6","author":"V Fatourechi","year":"2005","unstructured":"Fatourechi V (2005) Pretibial myxedema: pathophysiology and treatment options. Am J Clin Dermatol 6:295\u2013309","journal-title":"Am J Clin Dermatol"},{"key":"97_CR48","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.exer.2012.11.014","volume":"107","author":"P Zhao","year":"2013","unstructured":"Zhao P, Deng Y, Gu P, Wang Y, Zhou H, Hu Y, Chen P, Fan X (2013) Insulin-like growth factor 1 promotes the proliferation and adipogenesis of orbital adipose-derived stromal cells in thyroid-associated ophthalmopathy. Exp Eye Res 107:65\u201373","journal-title":"Exp Eye Res"},{"key":"97_CR49","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1089\/10507250050137761","volume":"10","author":"B Rapoport","year":"2000","unstructured":"Rapoport B, Alsabeh R, Aftergood D, McLachlan SM (2000) Elephantiasic pretibial myxedema: insights into and a hypothesis regarding the pathogenesis of extrathyroidal manifestations of Graves\u2019 disease. Thyroid 10:685\u2013692","journal-title":"Thyroid"},{"key":"97_CR50","first-page":"620","volume":"10","author":"TF Davies","year":"2000","unstructured":"Davies TF (2000) Trauma and pressure explain the clinical presentation of the Graves\u2019 disease Triad. Thyroid 10:620\u2013630","journal-title":"Thyroid"},{"key":"97_CR51","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/j.1365-2230.2008.03109.x","volume":"35","author":"SA Rice","year":"2010","unstructured":"Rice SA, Peden NR, McGlynn S, Morton C (2010) Atypical presentation of infiltrative thyroid dermopathy. Clin Exp Dermatol 35:56\u201358","journal-title":"Clin Exp Dermatol"},{"key":"97_CR52","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1089\/thy.2010.1634","volume":"20","author":"MN Stan","year":"2010","unstructured":"Stan MN, Bahn RS (2010) Risk factors for development or deterioration of Graves\u2019 ophthalmopathy. Thyroid 20:777\u2013783","journal-title":"Thyroid"},{"key":"97_CR53","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1136\/bjo.2008.141168","volume":"92","author":"N Lois","year":"2008","unstructured":"Lois N, Abdelkader E, Reglitz K, Garden C, Ayres JG (2008) Environmental tobacco smoke exposure and eye disease. Br J Ophthalmol 92:1304\u20131310","journal-title":"Br J Ophthalmol"},{"key":"97_CR54","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/BF03345276","volume":"27","author":"L Hegedus","year":"2004","unstructured":"Hegedus L, Brix TH, Vestergaard P (2004) Relationship between cigarette smoking and Graves\u2019 ophthalmopathy. J Endocrinol Invest 27:265\u2013271","journal-title":"J Endocrinol Invest"},{"key":"97_CR55","doi-asserted-by":"crossref","first-page":"5435","DOI":"10.1210\/jc.2002-020746","volume":"87","author":"V Fatourechi","year":"2002","unstructured":"Fatourechi V, Ahmed DD, Schwartz KM (2002) Thyroid acropachy report of 40 patients treated in a single institution in a 26-year period. J Clin Endocrinol Metab 87:5435\u20135441","journal-title":"J Clin Endocrinol Metab"},{"key":"97_CR56","first-page":"7117","volume":"12","author":"N Noppakun","year":"1986","unstructured":"Noppakun N, Bancherun K, Chandarapracert S (1986) Unusual location of localized myxedema in Graves\u2019 disease: report of three cases. Arch Dermatol 12:7117\u20137721","journal-title":"Arch Dermatol"},{"key":"97_CR57","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJM197606172942507","volume":"294","author":"M Siegler","year":"1976","unstructured":"Siegler M, Retetoff S (1976) Pretibial myxedema: a reversible cause of foot drop due to entrapment of the peroneal nerve. N Engl J Med 294:1383\u20131384","journal-title":"N Engl J Med"},{"key":"97_CR58","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1111\/j.1600-0560.2010.01537.x","volume":"37","author":"DM Eslton","year":"2010","unstructured":"Eslton DM (2010) Stasis mucinosis. J Cutan Pathol 37:1024","journal-title":"J Cutan Pathol"},{"key":"97_CR59","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1210\/jcem-19-10-1323","volume":"19","author":"LR King","year":"1959","unstructured":"King LR, Braunstein H, Chambers D et al (1959) A case study of peculiar soft-tissue and bony changes in association with thyroid disease. J Clin Endocrinol Metab 19:1323\u20131330","journal-title":"J Clin Endocrinol Metab"},{"key":"97_CR60","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1210\/jc.2006-1824","volume":"92","author":"TJ Cawood","year":"2007","unstructured":"Cawood TJ, Moriarty P, O\u2019Farrelly C, O\u2019Shea D (2007) Smoking and thyroid-associated ophthalmopathy: a novel explanation of the biological link. J Clin Endocrinol Metab 92:59\u201364","journal-title":"J Clin Endocrinol Metab"},{"key":"97_CR61","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1001\/archopht.123.4.491","volume":"123","author":"M Farid","year":"2005","unstructured":"Farid M, Roch-Levecq AC, Levi L, Brody BL, Granet DB, Kikkawa DO (2005) Psychological disturbance in Graves ophthalmopathy. Arch Ophthalmol 123:491\u2013496","journal-title":"Arch Ophthalmol"},{"key":"97_CR62","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/j.1365-2265.2005.02352.x","volume":"63","author":"GJ Kahaly","year":"2005","unstructured":"Kahaly GJ, Petrak F, Hardt J, Pitz S, Egle UT (2005) Psychosocial morbidity of Graves\u2019 orbitopathy. Clin Endocrinol (Oxf) 63:395\u2013402","journal-title":"Clin Endocrinol (Oxf)"},{"key":"97_CR63","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1089\/thy.2012.0258","volume":"23","author":"MN Stan","year":"2013","unstructured":"Stan MN, Duraski JM, Brito JP, Bhagra S, Thapa P, Bahn RS (2013) Cohort study on radioactive iodine -induced hypothyroidism: implications for Graves\u2019 ophthalmopathy and optimal timing for thyroid hormone assessment. Thyroid 23:620\u2013625","journal-title":"Thyroid"},{"key":"97_CR64","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1210\/jc.2010-2329","volume":"96","author":"L Bartalena","year":"2011","unstructured":"Bartalena L (2011) The dilemma of how to manage Graves\u2019 hyperthyroidism in patients with associated orbitopathy. J Clin Endocrinol Metab 96:592\u2013599","journal-title":"J Clin Endocrinol Metab"},{"key":"97_CR65","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1210\/jc.2006-1800","volume":"92","author":"F Menconi","year":"2007","unstructured":"Menconi F, Marin\u00f2 M, Pinchera A, Rocchi R, Mazzi B, Nardi M, Bartalena L, Marcocci C (2007) Effects of total thyroid ablation versus near-total thyroidectomy alone on mild to moderate Graves\u2019 orbitopathy treated with intravenous glucocorticoids. J Clin Endocrinol Metab 92:1653\u20131658","journal-title":"J Clin Endocrinol Metab"},{"key":"97_CR66","doi-asserted-by":"crossref","first-page":"E44","DOI":"10.1210\/jc.2011-2077","volume":"97","author":"M Leo","year":"2012","unstructured":"Leo M, Marcocci C, Pinchera A, Nardi M, Megna L, Rocchi R, Latrofa F, Altea MA, Mazzi B, Sisti E, Profilo MA, Marin\u00f2 M (2012) Outcome of Graves\u2019 orbitopathy after total thyroid ablation and glucocorticoid treatment: follow-up of a randomized clinical trial. J Clin Endocrinol Metab 97:E44\u2013E48","journal-title":"J Clin Endocrinol Metab"},{"key":"97_CR67","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1007\/s12020-011-9559-x","volume":"41","author":"A Bellis De","year":"2013","unstructured":"De Bellis A, Conzo G, Cennamo G, Pane E, Bellastella G, Colella C, Iacovo AD, Paglionico VA, Sinisi AA, Wall JR, Bizzarro A, Bellastella A (2013) Time course of Graves\u2019 ophthalmopathy after total thyroidectomy alone or followed by radioiodine therapy: a 2-year longitudinal study. Endocrine 41:320\u2013326","journal-title":"Endocrine"},{"key":"97_CR68","doi-asserted-by":"crossref","unstructured":"Moleti M, Violi MA, Montanini D, Trombetta C, Di Bella B, Sturniolo G, Presti S, Alibrandi A, Campenn\u00ec A, Baldari S, Trimarchi F, Vermiglio F (2014) Radioiodine ablation of post-surgical thyroid remnants after treatment with recombinant human TSH (rhTSH in patients with moderate-to-severe Graves\u2019 orbitopathy (GO): a prospective, randomized, single-blind clinical trial. J Clin Endocrinol Metab 99:1783\u20131789","DOI":"10.1210\/jc.2013-3093"},{"key":"97_CR69","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1089\/10507250360731541","volume":"13","author":"V Fatourechi","year":"2003","unstructured":"Fatourechi V, Bartley GB, Eghbali-Fatourechi GZ, Pwoel CC, Ahmed DF, Garrity JA (2003) Graves\u2019 dermopathy and acropachy are markers of severe Graves\u2019 ophthalmopathy. Thyroid 13:1141\u20131144","journal-title":"Thyroid"},{"key":"97_CR70","doi-asserted-by":"crossref","first-page":"665","DOI":"10.2169\/internalmedicine.49.2617","volume":"49","author":"N Takasu","year":"2010","unstructured":"Takasu N, Higa H, Kinjou Y (2010) Treatment of pretibial myxedema (PTM) with topical steroid ointment application with sealing cover (steroid occlusive dressing technique: steroid ODT) in Graves\u2019 patients. Intern Med 49:665\u2013669","journal-title":"Intern Med"},{"key":"97_CR71","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1067\/mjd.2002.119655","volume":"46","author":"WS Susser","year":"2002","unstructured":"Susser WS, Heermans AG, Chapman MS, Baughman RD (2002) Elephantiasic pretibial myxedema: a novel treatment for an uncommon disorder. J Am Acad Dermatol 46:723\u2013726","journal-title":"J Am Acad Dermatol"},{"key":"97_CR72","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1089\/thy.2012.0429","volume":"23","author":"G Vannucchi","year":"2013","unstructured":"Vannucchi G, Campi I, Covelli D, Forzenigo L, Beck-Peccoz P, Salvi M (2013) Treatment of pretibial myxedema with dexamethasone injected subcutaneously by mesotherapy needles. Thyroid 23:626\u2013632","journal-title":"Thyroid"},{"key":"97_CR73","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1089\/thy.2010.0268","volume":"21","author":"A Deng","year":"2011","unstructured":"Deng A, Song D (2011) Multipoint subcutaneous injection of long-acting glucocorticid as a cure for pretibial myxedema. Thyroid 21:83\u201385","journal-title":"Thyroid"},{"key":"97_CR74","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1111\/j.1440-0960.2010.00693.x","volume":"53","author":"C Heyes","year":"2012","unstructured":"Heyes C, Nolan R, Leahy M, Gebauer K (2012) Treatment-resistant elephantiasic thyroid dermopathy responding to rituximab and plasmapheresis. Austr J Dermatol 53:e1\u2013e4","journal-title":"Austr J Dermatol"},{"key":"97_CR75","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1089\/thy.1994.4.399","volume":"4","author":"A Antonelli","year":"1994","unstructured":"Antonelli A, Navarranne A, Palla R, Alberti B, Saracino A, Mestre C, Roger P, Agostini S, Baschieri L (1994) Pretibial myxedema and high-dose intravenous immunoglobulin. Thyroid 4:399\u2013408","journal-title":"Thyroid"},{"key":"97_CR76","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1159\/000356042","volume":"2","author":"L Bartalena","year":"2013","unstructured":"Bartalena L (2013) Graves\u2019 orbitopathy: imperfect treatments for a rare disease. Eur Thyroid J 2:259\u2013269","journal-title":"Eur Thyroid J"},{"key":"97_CR77","doi-asserted-by":"crossref","unstructured":"Bartalena L (2014) Rituximab, adalimumab, etanercept, tocilizumab: are biologics the future for Graves\u2019 orbitopathy? Ophthal Plast Reconstr Surg (In press)","DOI":"10.1097\/IOP.0000000000000221"},{"key":"97_CR78","doi-asserted-by":"crossref","first-page":"4291","DOI":"10.1210\/jc.2013-1804","volume":"98","author":"M Salvi","year":"2013","unstructured":"Salvi M, Vannucchi G, Beck-Peccoz P (2013) Potential utility of rituximab for Graves\u2019 orbitopathy. J Clin Endocrinol Metab 98:4291\u20134299","journal-title":"J Clin Endocrinol Metab"},{"key":"97_CR79","first-page":"CD009226","volume":"5","author":"N Minakaran","year":"2013","unstructured":"Minakaran N, Ezra DG (2013) Rituximab for thyroid-associated ophthalmopathy. Cochrane Datab Syst Rev 5:CD009226. doi: 10.1002\/14651858.CD009226.pub2","journal-title":"Cochrane Datab Syst Rev"},{"key":"97_CR80","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1038\/sj.eye.6701768","volume":"19","author":"D Paridaens","year":"2005","unstructured":"Paridaens D, van den Bosch WA, van der Loos TL, Krenning EP, van Hagen PM (2005) The effect of etanercept on Graves\u2019 ophthalmopathy: a pilot study. Eye 19:1286\u20131289","journal-title":"Eye"},{"key":"97_CR81","doi-asserted-by":"crossref","unstructured":"Ayabe R, Rootman DB, Hwuang CJ et al. (2014) Adalimumab as steroid sparing treatment of inflammatory stage thyroid eye disease. Ophthal Plast Reconstr Surg (In press)","DOI":"10.1097\/IOP.0000000000000211"},{"key":"97_CR82","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1097\/IOP.0000000000000037","volume":"30","author":"JV P\u00e9rez-Moreiras","year":"2014","unstructured":"P\u00e9rez-Moreiras JV, Alvarez-Lopez A, Cardiel Gomez E (2014) Treatment of active corticosteroid-resistant Graves\u2019 orbitopathy. Ophthal Plast Reconstr Surg 30:162\u2013167","journal-title":"Ophthal Plast Reconstr Surg"},{"key":"97_CR83","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1167\/iovs.08-2443","volume":"50","author":"L Steensel van","year":"2009","unstructured":"van Steensel L, Paridaens D, Schrijver B, Dingjan GM, van Daele PL, van Hagen PM, van den Bosch WA, Drexhage HA, Hooijkaas H, Dik WA (2009) Imatinib mesylate and AMN107 inhibit PDGF-signaling in orbital fibroblasts: a potential treatment for Graves\u2019 ophthalmopathy. Invest Ophtalmol Vis Sci 50:3091\u20133098","journal-title":"Invest Ophtalmol Vis Sci"},{"key":"97_CR84","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1210\/jc.2013-1149","volume":"98","author":"AF Turcu","year":"2012","unstructured":"Turcu AF, Kumar S, Neumann S, Coenen M, Iyer S, Chiriboga P, Gershengorm MC, Bahn RS (2012) A small molecule antagonist inhibits thyrotropin receptor antibody-induced orbital fibroblasts functions involved in the pathogenesis of Graves\u2019 ophthalmopathy. J Clin Endocrinol Metab 98:2153\u20132159","journal-title":"J Clin Endocrinol Metab"},{"key":"97_CR85","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1210\/jc.2013-1004","volume":"98","author":"TJ Smith","year":"2013","unstructured":"Smith TJ (2013) Is IGF-I receptor a target for autoantibody generation in Graves\u2019 disease? J Clin Endocrinol Metab 98:515\u2013518","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-014-0097-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40618-014-0097-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-014-0097-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T16:37:23Z","timestamp":1716827843000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40618-014-0097-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6,10]]},"references-count":85,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["97"],"URL":"https:\/\/doi.org\/10.1007\/s40618-014-0097-2","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,6,10]]}}}